IGFBP1 and cardioembolic stroke: Regarding IGFBP-1 after 3 months, it was associated with mortality in cardioembolic stroke (crude HR 3.80, 95% CI 1.32–10.9, and adjusted HR 4.76, 95% CI 1.42–16.0, Table 5B) and cryptogenic stroke (crude HR 5.29, 95% CI 1.27–22.0, and adjusted HR 5.53, 95% CI 1.12–27.3, Table 5B).